Oxfordshire Sedentariness, Obesity & Cardiometabolic Risk in Adolescents - a Trial of Exercise in Schools (OxSOCRATES)
Primary Purpose
Overweight/Obesity, Adolescent
Status
Recruiting
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Intervention Group
Sham-Exercise Group
Sponsored by
About this trial
This is an interventional prevention trial for Overweight/Obesity, Adolescent focused on measuring Obesity, Cardiometabolic, Adolescence, Exercise
Eligibility Criteria
Inclusion Criteria:
- Participants willing and able to register their informed assent and whose parent(s)/guardian(s), give informed consent for participation of their child in the study
- Age and sex-appropriate BMI scores using the World Health Organisation standards for obesity and normal weight
- Objectively measured physical activity
Exclusion Criteria:
- Contraindications for exercise intervention as determined by the Physical Activity Readiness Questionnaire
- Safety issues due to behavioural/intellectual limitations
- Medical Conditions such as neurological disorders or uncontrolled epilepsy
- Allergies to dairy
- Type 1 diabetes
- Pregnancy
- Contraindications for Magnetic Resonance scans
Sites / Locations
- Oxford Centre for Clinical Magnetic Resonance Research (OCMR)Recruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Sham Comparator
Arm Label
Intervention Group
Sham-Exercise Group
Arm Description
The intervention group will take part in three 1-hour targeted moderate-to-vigorous physical activity (MVPA) gym-based group exercise sessions per week for eight weeks with individualised prescriptions.
The shame-exercise group will complete three sham exercise group sessions per week for eight weeks (including stretching, coordination and balance activities and very low-level cardiovascular activities that mimic the types of exercise done in the intervention group).
Outcomes
Primary Outcome Measures
Cardiometabolic phenotype score
An additive cardiometabolic phenotype score will be defined as the sum of the z-scores of known elements of cardiometabolic risk with each element scored such that a positive value indicates greater risk.
The following elements will be scored positively in the risk model: low cardiac phosphocreatine and adenosine triphosphate (PCr/ATP) ratio z-score by phosphate Magnetic Resonance Spectroscopy (MRS), high aortic pulse wave velocity z-score (arterial stiffness) by Magnetic Resonance (MR), high Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) z-score (insulin resistance), high visceral fat mass z-score by T2*-IDEAL MR, high left ventricular mass z-score by MR, low peak left ventricular diastolic filling rate z-score by MR, and high 24 hour ambulatory blood pressure z-score.
Superior mesenteric artery blood flow after a meal challenge
Assessing the change of blood flow (l/min) in the superior mesenteric artery in response to a meal challenge, measured by phase-contrast MR.
Muscle acetylcarnitine
Increased acetylcarnitine is a marker of skeletal muscle metabolism, measured by MRS.
Triglyceride
Blood plasma (mmol/l) post prandial triglyceride response.
Secondary Outcome Measures
Echocardiography - Diastolic Function
Early mitral inflow velocity and mitral annular early diastolic velocity ratio (E/E' ratio) will be derived from mitral valve inflow Doppler and Tissue Doppler Imaging of the left ventricular myocardium.
High Density Lipoprotein (HDL)
Blood samples taken at rest, measuring cholesterol (mmol/L).
Low Density Lipoprotein (LDL)
Blood samples taken at rest, measuring cholesterol (mmol/L).
Alanine aminotransferase (ALT)
Blood samples taken at rest measuring liver dysfunction (mmol/L).
Aspartate Aminotransferase (AST)
Blood samples taken at rest measuring liver dysfunction (mmol/L).
Alkaline Phosphatase (ALP)
Blood samples taken at rest measuring liver dysfunction (mmol/L).
Total Bilirubin (T.Bil)
Blood samples taken at rest measuring liver dysfunction (mmol/L).
Haemoglobin A1c (HbA1c)
Blood samples taken at rest (mmol/L).
Glucose
Serial measures after meal (mmol/L).
Insulin
Serial measures after meal (mmol/L).
Full Blood Count (FBC)
Blood samples taken at rest.
High Sensitivity C-reactive protein (CRP)
Blood samples taken at rest (mmol/L).
Food Preference Questionnaire
United Kingdom (UK) Biobank Food preference Questionnaire.
Health Behaviour Questionnaire
The Health Behaviour in School-Aged Children (HSBC).
Weight Related Eating Questionnaire
Weight-Related Eating Questionnaire (WREQ).
Self-Regulation of Eating Behaviour Questionnaire
Self-Regulation of Eating Behaviour Questionnaire (SREBQ).
Physical Activity Levels
Wrist-worn triaxial accelerometers will sample physical activity levels over seven days.
Skeletal muscle lipid
skeletal muscle lipid measured MRS.
Cardiac PCr/ATP ratio
Cardiac PCr/ATP is a measure of myocardial energetics, measure by MRS.
Cardiac lipids
Cardiac lipids is a measure of myocardial lipid spill over, measure by MRS.
Aortic pulse wave velocity
An index of arterial stiffness, measured by MR.
Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Measures insulin resistance.
Visceral fat mass
Associated with adverse cardiometabolic changes in adolescents, measured by T2*-IDEAL MR.
Left ventricular mass
A measure of early cardiometabolic dysfunction, measured MR.
Peak left ventricular diastolic filling rate
Indicator of early cardiovascular damage, measure by MR.
Blood pressure
24 hour ambulatory systolic and diastolic blood pressure, measured by SunTech Oscar 2 monitor.
Skeletal muscle glycogen
Increased glycogen is a marker of skeletal muscle metabolism, measured my MRS.
Participant experience
Optional exit interview of study experience.
Full Information
NCT ID
NCT04118543
First Posted
September 4, 2019
Last Updated
August 4, 2021
Sponsor
University of Oxford
Collaborators
Oxford Brookes University
1. Study Identification
Unique Protocol Identification Number
NCT04118543
Brief Title
Oxfordshire Sedentariness, Obesity & Cardiometabolic Risk in Adolescents - a Trial of Exercise in Schools
Acronym
OxSOCRATES
Official Title
Oxfordshire Sedentariness, Obesity & Cardiometabolic Risk in Adolescents - a Trial of Exercise in Schools
Study Type
Interventional
2. Study Status
Record Verification Date
August 2021
Overall Recruitment Status
Recruiting
Study Start Date
October 1, 2019 (Actual)
Primary Completion Date
July 2023 (Anticipated)
Study Completion Date
July 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Oxford
Collaborators
Oxford Brookes University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Obesity is a major cardiovascular disease (CVD) risk factor that is rising fastest in children. Prevention of its damaging effects should begin earlier before they become irreversible. Pilot data identified novel markers of cardiometabolic dysfunction that may be better than body mass index at stratifying risk and as targets for CVD prevention in the young. Advanced imaging, blood tests and a meal-challenge will be used to comprehensively characterise how early metabolic dysfunction (liver and muscle fat, insulin resistance) affects cardiovascular health (arterial stiffness, myocardial energetics, gut vasoreactivity, diastolic function, blood pressure trajectory, left ventricular hypertrophy) in 210 adolescents (110 obese, 50 sedentary normal-weight, 50 high-activity). Reversibility of this phenotype will be tested in the obese by randomised controlled trial, comparing 8-week supervised exercise to a low-activity sham intervention. This study will provide the platform for developing practical, effective CVD prevention in children that is not simply focused on weight-loss.
Detailed Description
Objectives and Outcome measures
This proposal aims to (1) improve identification of early cardiometabolic dysfunction in children and (2) investigate the reversibility of this dysfunction through exercise. The study will provide the platform for developing practical, effective primordial CVD prevention strategies and the identification of novel early therapeutic targets.
Study Design
This study combines elements of both observational and interventional study designs. A prospective, cross-sectional study of adolescents with 1-year follow-up is combined with a randomised placebo (sham-exercise)-controlled trial (RCT) of eight-weeks of supervised, individualised exercise in an obese sub-population. The RCT is of an established, standardised exercise programme that is low-risk. Group allocation will be known only to the exercise physiologist and staff carrying out the exercise intervention.
Fitness tests will be carried out in schools and in our exercise laboratory, which will provide opportunities to support questionnaire completion, fit accelerometers, fit and return ambulatory blood pressure monitors and address participant questions or concerns. In addition, participants will visit The Oxford Centre for Clinical Magnetic Resonance Research (OCMR) for the initial assessment and for the follow-up assessment for those participants in the obese group.
Participants
210 participants will be recruited, 110 of these will be obese, 50 will be normal weight and their activity will be matched to the obese group and therefore, relatively sedentary. 50 normal weight controls will be selected on the basis of high levels of physical activity. The 110 obese participants will be randomised (1:1) to exercise intervention or a low-intensity sham exercise placebo intervention. These numbers are justified by a priori power calculations and take into account potential withdrawals at an attrition rate of 10% that is compatible with recent studies in the same or similar populations (e.g. Fit to Study). Compliance with the interventions will be increased by carrying out the interventions through an online remote methodology which can also be implemented in a school setting, predominantly during mandatory physical education (PE) lessons. Trained, experienced staff will supervise the exercise sessions, ensuring participant engagement with the activities by measuring heart rate and physical activity levels.
Recruitment
Pre-screening will be done through schools who will write to families informing them that their children will be taking part in an enhanced P.E. lesson at school that includes a fitness and health screening session. As part of this, the children will be asked to wear an activity watch (accelerometer) for a week. The session will explore many aspects of their agility and fitness and assess their muscle strength, power, motor skills, speed, endurance and flexibility, adjusted for their physical size (height and weight). The lesson will be educational, giving personalised feedback to the children on their strengths and how to improve on areas where they are less strong. The school will retain a file linking the children's names to random identifiers but the researchers will not have access to, or retain, any identifiable information. Parents will be sent a letter giving them the opportunity to withdraw their children from this health screening session and explaining that researchers may ask the school to contact them again on their behalf if their children are eligible for study participation on the basis of their fitness assessment. Children who are withdrawn by their parents will participate in their usual P.E. lesson.
Recruitment will be done by letters to parents, delivered via the schools. Recruitment from an established population already in contact with the investigators research group should increase participation rates. It is difficult to precisely estimate the proportion of participants who fulfil the inclusion/exclusion criteria but it is assumed an obesity rate (BMI z-score (WHO) > 2) of approximately 20%.
In addition to the school screening recruitment, participants may also volunteer to take part in the study through our online advertisement and social media campaign. Children who express an interest will be invited to contact the study team so that an initial health assessment can be completed and an information pack can be provided. This pack will contain participant information sheets and consent forms, and will collect information needed for BMI z-score calculation. Then potentially eligible participants will be invited to complete physical activity questionnaires to determine eligibility and group allocation. This is to avoid any unnecessary testing on ineligible participants at university sites and provides a suitable remote method to differentiate between active and inactive participants.
Screening
Pre-stratification of the potential population for recruitment will be carried out, based on BMI and activity levels. Obese and normal weight groups will be approached for recruitment sequentially, according to their rank position within their respective BMI-based criteria in order to maximise the difference between groups (e.g. the most obese will be approached first for the obese group). The normal weight group will be further stratified according to activity levels such that half of this group matches the obesity group for activity whilst the other half are highly-active individuals. Again, individuals within this subgroup will be approached according to their rank position in the distribution of activity such that the most active are preferred in order to maximise the difference between groups.
Informed Consent
Participant's parents/guardians will be asked to sign and date the latest approved version of the Informed Consent before any study-specific procedures are performed. The latest approved Participant Information sheet will be provided to them and verbal explanations will also be provided ensuring that all of the following information has been presented and understood: the exact nature of the study; what it will involve for the participant; the implications and constraints of the protocol; and all known risks or benefits involved in taking part.
Participants will be told that they are free to withdraw from the study at any time and for any reason without being required to give a reason for their withdrawal. The participant will be allowed as much time as they wish to consider the information, and the opportunity to question the Investigator, their General Practitioner (GP) or other independent parties to decide whether they will participate in the study. Once these conditions are satisfied, written Informed Consent will be obtained by means of participant dated signature and dated signature of the person who presented and obtained the Informed Consent. The person taking consent will be a qualified member of the study team with a complete understanding of the study and with the authorisation of the Principal Investigator. A copy of the signed Informed Consent will be given to the participant and the original signed form will be retained at the study site.
Randomisation
Random allocation of members of the obese group to a sham fitness intervention or to a standardised exercise intervention will be carried out using an online randomisation process. The analysis will be carried out on an "intention-to-treat" basis when participants do not complete all elements of the data collection process and single-blinding will be maintained such that members of the team carrying out procedures at OCMR e.g. MRI and those involved in the data analysis are blinded to the allocation of intervention and sham groups. All data acquired at OCMR will be identified by a unique study number only. Inadvertent un-blinding will result in the exclusion of that individual's data from the analysis.
Incidental findings
Cardiovascular findings will be dealt with by the PI or another MRI-trained Consultant Paediatric Cardiologist. Findings in other imaging will be reviewed by the study Paediatric Radiologist. OCMR standard operation procedures (SOPs) for dealing with cardiac and non-cardiac incidental findings, respectively will be followed. Participants will not be informed of incidental findings on the day and will only be contacted after they have been formally reviewed and if a concern remains that further investigation is required.
Discontinuation or withdrawal of participants from the study
Each participant will have the right to withdraw from the study at any time. In addition, participation in the study may be discontinued at any time if the Investigator considers it necessary for any reason, including but not limited to: Pregnancy, ineligibility (either arising during the study or retrospectively, having been overlooked at screening), a significant protocol deviation, significant non-compliance with the exercise regimen or other study requirements, withdrawal of consent, and loss to follow-up. Data gathered to that point will be included in the analysis under an intention-to-treat principle. Where possible, further recruitment will be carried out to compensate for data loss resulting from early discontinuation of participation. The reason for all withdrawals will be recorded in the Case Report Form.
Confounding Factors
The exercise intervention RCT will be carried out over 8 weeks. The MRI scan operator will be blinded to RCT group allocations and all analyses will be carried out on anonymised data. Confounding factors in the observational part of the study will be addressed by matching of groups for age, sex, height, pubertal status and by matching the normal-weight sedentary group on activity level with the obese group. Questionnaires on cardiometabolic risk factors such as diet and sedentary behaviour will be used to quantify potential confounders. At least 24 hours prior to study visits, participants will be asked to avoid strenuous exercise, not smoke or drink alcohol, and eat a standardised evening meal before fasting in the morning.
Analysis
Analyses in the RCT will be carried out on an "intention-to-treat" basis. Secondary exploratory analysis will be to explore mechanisms
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Overweight/Obesity, Adolescent
Keywords
Obesity, Cardiometabolic, Adolescence, Exercise
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
210 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Intervention Group
Arm Type
Experimental
Arm Description
The intervention group will take part in three 1-hour targeted moderate-to-vigorous physical activity (MVPA) gym-based group exercise sessions per week for eight weeks with individualised prescriptions.
Arm Title
Sham-Exercise Group
Arm Type
Sham Comparator
Arm Description
The shame-exercise group will complete three sham exercise group sessions per week for eight weeks (including stretching, coordination and balance activities and very low-level cardiovascular activities that mimic the types of exercise done in the intervention group).
Intervention Type
Other
Intervention Name(s)
Intervention Group
Other Intervention Name(s)
Exercise Intervention Group
Intervention Description
Each participant assigned to this intervention arm will start with a progressive cardiovascular warm-up for 10mins. The main exercise session will consist of resistance and cardiovascular based exercises targeting the whole body, which will last for 35-40mins. A cool-down period will follow lasting 5-10mins.
Intervention Type
Other
Intervention Name(s)
Sham-Exercise Group
Intervention Description
Each participant assigned to this intervention arm will start with a warm-up for 10mins, which will be controlled in order to reduce any cardiovascular training effects. The sham-exercise sessions will consist of stretching, coordination and balance activities and very low-level cardiovascular activities that mimic the types of exercise done in the intervention group. This will last for 35-40mins, followed by a 5-10min cool-down.
Primary Outcome Measure Information:
Title
Cardiometabolic phenotype score
Description
An additive cardiometabolic phenotype score will be defined as the sum of the z-scores of known elements of cardiometabolic risk with each element scored such that a positive value indicates greater risk.
The following elements will be scored positively in the risk model: low cardiac phosphocreatine and adenosine triphosphate (PCr/ATP) ratio z-score by phosphate Magnetic Resonance Spectroscopy (MRS), high aortic pulse wave velocity z-score (arterial stiffness) by Magnetic Resonance (MR), high Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) z-score (insulin resistance), high visceral fat mass z-score by T2*-IDEAL MR, high left ventricular mass z-score by MR, low peak left ventricular diastolic filling rate z-score by MR, and high 24 hour ambulatory blood pressure z-score.
Time Frame
Changes from baseline - 8 weeks
Title
Superior mesenteric artery blood flow after a meal challenge
Description
Assessing the change of blood flow (l/min) in the superior mesenteric artery in response to a meal challenge, measured by phase-contrast MR.
Time Frame
Changes from baseline - 8 weeks
Title
Muscle acetylcarnitine
Description
Increased acetylcarnitine is a marker of skeletal muscle metabolism, measured by MRS.
Time Frame
Changes from baseline - 8 weeks
Title
Triglyceride
Description
Blood plasma (mmol/l) post prandial triglyceride response.
Time Frame
Changes from baseline - 8 weeks
Secondary Outcome Measure Information:
Title
Echocardiography - Diastolic Function
Description
Early mitral inflow velocity and mitral annular early diastolic velocity ratio (E/E' ratio) will be derived from mitral valve inflow Doppler and Tissue Doppler Imaging of the left ventricular myocardium.
Time Frame
Changes from baseline - 8 weeks
Title
High Density Lipoprotein (HDL)
Description
Blood samples taken at rest, measuring cholesterol (mmol/L).
Time Frame
Changes from baseline - 8 weeks
Title
Low Density Lipoprotein (LDL)
Description
Blood samples taken at rest, measuring cholesterol (mmol/L).
Time Frame
Changes from baseline - 8 weeks
Title
Alanine aminotransferase (ALT)
Description
Blood samples taken at rest measuring liver dysfunction (mmol/L).
Time Frame
Changes from baseline - 8 weeks
Title
Aspartate Aminotransferase (AST)
Description
Blood samples taken at rest measuring liver dysfunction (mmol/L).
Time Frame
Changes from baseline - 8 weeks
Title
Alkaline Phosphatase (ALP)
Description
Blood samples taken at rest measuring liver dysfunction (mmol/L).
Time Frame
Changes from baseline - 8 weeks
Title
Total Bilirubin (T.Bil)
Description
Blood samples taken at rest measuring liver dysfunction (mmol/L).
Time Frame
Changes from baseline - 8 weeks
Title
Haemoglobin A1c (HbA1c)
Description
Blood samples taken at rest (mmol/L).
Time Frame
Changes from baseline - 8 weeks
Title
Glucose
Description
Serial measures after meal (mmol/L).
Time Frame
Changes from baseline - 8 weeks
Title
Insulin
Description
Serial measures after meal (mmol/L).
Time Frame
Changes from baseline - 8 weeks
Title
Full Blood Count (FBC)
Description
Blood samples taken at rest.
Time Frame
Changes from baseline - 8 weeks
Title
High Sensitivity C-reactive protein (CRP)
Description
Blood samples taken at rest (mmol/L).
Time Frame
Changes from baseline - 8 weeks
Title
Food Preference Questionnaire
Description
United Kingdom (UK) Biobank Food preference Questionnaire.
Time Frame
Changes from baseline - 4 weeks and 8 weeks
Title
Health Behaviour Questionnaire
Description
The Health Behaviour in School-Aged Children (HSBC).
Time Frame
Changes from baseline - 4 weeks and 8 weeks
Title
Weight Related Eating Questionnaire
Description
Weight-Related Eating Questionnaire (WREQ).
Time Frame
Changes from baseline - 4 weeks and 8 weeks
Title
Self-Regulation of Eating Behaviour Questionnaire
Description
Self-Regulation of Eating Behaviour Questionnaire (SREBQ).
Time Frame
Changes from baseline - 4 weeks and 8 weeks
Title
Physical Activity Levels
Description
Wrist-worn triaxial accelerometers will sample physical activity levels over seven days.
Time Frame
Changes from baseline - 8 weeks
Title
Skeletal muscle lipid
Description
skeletal muscle lipid measured MRS.
Time Frame
Changes from baseline - 8 weeks
Title
Cardiac PCr/ATP ratio
Description
Cardiac PCr/ATP is a measure of myocardial energetics, measure by MRS.
Time Frame
Changes from baseline - 8 weeks
Title
Cardiac lipids
Description
Cardiac lipids is a measure of myocardial lipid spill over, measure by MRS.
Time Frame
Changes from baseline - 8 weeks
Title
Aortic pulse wave velocity
Description
An index of arterial stiffness, measured by MR.
Time Frame
Changes from baseline - 8 weeks
Title
Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Description
Measures insulin resistance.
Time Frame
Changes from baseline - 8 weeks
Title
Visceral fat mass
Description
Associated with adverse cardiometabolic changes in adolescents, measured by T2*-IDEAL MR.
Time Frame
Changes from baseline - 8 weeks
Title
Left ventricular mass
Description
A measure of early cardiometabolic dysfunction, measured MR.
Time Frame
Changes from baseline - 8 weeks
Title
Peak left ventricular diastolic filling rate
Description
Indicator of early cardiovascular damage, measure by MR.
Time Frame
Changes from baseline - 8 weeks
Title
Blood pressure
Description
24 hour ambulatory systolic and diastolic blood pressure, measured by SunTech Oscar 2 monitor.
Time Frame
Changes from baseline - 8 weeks
Title
Skeletal muscle glycogen
Description
Increased glycogen is a marker of skeletal muscle metabolism, measured my MRS.
Time Frame
Changes from baseline - 8 weeks
Title
Participant experience
Description
Optional exit interview of study experience.
Time Frame
At 8 weeks post baseline and 1 year follow
10. Eligibility
Sex
All
Minimum Age & Unit of Time
11 Years
Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Participants willing and able to register their informed assent and whose parent(s)/guardian(s), give informed consent for participation of their child in the study
Age and sex-appropriate BMI scores using the World Health Organisation standards for obesity and normal weight
Objectively measured physical activity
Exclusion Criteria:
Contraindications for exercise intervention as determined by the Physical Activity Readiness Questionnaire
Safety issues due to behavioural/intellectual limitations
Medical Conditions such as neurological disorders or uncontrolled epilepsy
Allergies to dairy
Type 1 diabetes
Pregnancy
Contraindications for Magnetic Resonance scans
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Alexander Jones, BM, BSc, FRCP, PhD
Phone
07423474923
Email
alexander.jones@paediatrics.ox.ac.uk
First Name & Middle Initial & Last Name or Official Title & Degree
Benjamin D Weedon, BSc, MSc, PhD
Phone
01865 483272
Email
b.weedon@brookes.ac.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alexander Jones, BM, BSc, FRCP, PhD
Organizational Affiliation
University of Oxford
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Helen Dawes, PhD
Organizational Affiliation
Oxford Brookes University
Official's Role
Study Director
Facility Information:
Facility Name
Oxford Centre for Clinical Magnetic Resonance Research (OCMR)
City
Oxford
State/Province
Oxfordshire
ZIP/Postal Code
OX3 9DU
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alexander Jones, BM, BSc, FRCP, PhD
Email
alexander.jones@paediatrics.ox.ac.uk
First Name & Middle Initial & Last Name & Degree
Benjamin D Weedon, BSc, MSc, MCSP, PhD
Phone
01865483272
Email
b.weedon@brookes.ac.uk
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Oxfordshire Sedentariness, Obesity & Cardiometabolic Risk in Adolescents - a Trial of Exercise in Schools
We'll reach out to this number within 24 hrs